Peptide therapeutics for rare genetic metabolic diseases


Rhythm (NASDAQ: RYTM) is a biopharmaceutical company focused on developing peptide therapeutics for the treatment of rare genetic deficiencies that result in life‑threatening metabolic disorders. Rhythm’s lead peptide product candidate is setmelanotide, a first‑in‑class melanocortin‑4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity.


Year Invested: 2010
Location: Boston, Mass.
Visit: www.rhythmtx.com

Recent News

October 10, 2017
Rhythm Pharmaceuticals, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

October 4, 2017
Rhythm Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering

August 1, 2017
Rhythm Expands Executive Leadership Team

Read More News

Associated Team Members

Neil Exter
Partner